Novartis Bangladesh names a new leader for its Management team
In a significant move for the pharmaceutical sector in Bangladesh, Radiant Pharmaceuticals has acquired a controlling 60% stake in Novartis Bangladesh Limited (NBL), effective as of 14 July 2025. This acquisition marks a strategic shift for both companies, with the aim of strengthening Radiant's presence in the Bangladeshi market.
At the helm of Novartis Bangladesh is Musawath Shams Zahedee, who has been appointed as the new Managing Director. Zahedee, a director at Radiant and its affiliated companies, brings a wealth of experience to the role, having earned both undergraduate and postgraduate degrees from Cass Business School in the United Kingdom. Known for his strategic vision and ability to drive organizational growth, Zahedee is expected to align Novartis Bangladesh's strategy with Radiant's vision.
The acquisition is set to bolster Radiant's position in the pharmaceutical market, as it expands its product offerings and operational capacity. This move signifies Radiant's ambition to become a leading player in Bangladesh's pharmaceutical industry. The integration of Novartis Bangladesh's operations with Radiant's own will help in optimising resources and enhancing efficiency across both entities.
However, the acquisition process has faced legal challenges, with notices served to regulatory bodies regarding potential financial irregularities and money laundering concerns. These issues may impact the long-term success of Radiant's strategy for Novartis Bangladesh.
Beyond his corporate role, Zahedee is a sports patron, and an accomplished golfer. His appointment as Managing Director of Novartis Bangladesh follows the acquisition by Radiant Pharmaceuticals, marking a new chapter in the company's history. As the pharmaceutical sector in Bangladesh continues to evolve, the acquisition by Radiant Pharmaceuticals is set to have a significant impact on the industry's future.
The acquisition by Radiant Pharmaceuticals, that has placed Musawath Shams Zahedee as the new Managing Director of Novartis Bangladesh, aims to strategicly strengthen Radiant's presence in the Bangladeshi business sector, particularly within the pharmaceutical industry. However, the process has faced legal challenges related to potential financial irregularities and money laundering concerns, which may impact the long-term success of the business strategy for Novartis Bangladesh.
